Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FK419

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
The binding of platelet glycoprotein (GP) IIb/IIIa to fibrinogen is the final common pathway in platelet aggregation, a process… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2005
2005
The discovery of the non-peptide antiplatelet injectable agent FK419 is reported. Based on the beta-turn structure of RGD peptide… Expand
Review
2005
Review
2005
The antithrombotic efficacy of FK419, a novel nonpeptide platelet glycoprotein IIb/IIIa antagonist, was compared with tirofiban… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2005
2005
Intracerebral hemorrhage (ICH) is the most serious side effect of antithrombotic agents, especially in cases of cerebrovascular… Expand
2004
2004
We compared the antithrombotic efficacy of FK419 [(S)-2-acetylamino-3-[(R)-[1-[3-(piperidin-4-yl)propionyl]piperidin-3-ylcarbonyl… Expand
2004
2004
Platelet activation and subsequent aggregation play a key role in the pathogenesis of ischemic brain damage. Recent studies… Expand
  • table 1
  • table 2
  • figure 2
  • figure 3
  • table 3